Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.

NCT05059522 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05059522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05059522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 29, 2021
Completion date
December 31, 2026
Enrollment
77 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, nsclc, ovarian cancer, solid tumors, urothelial cancer